PMID- 32337210
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 8
IP  - 7
DP  - 2020 Apr 6
TI  - Clinical effects of apatinib mesylate for treatment of multiple brain 
      micrometastases: Two case reports.
PG  - 1326-1336
LID - 10.12998/wjcc.v8.i7.1326 [doi]
AB  - BACKGROUND: Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor. 
      Apatinib has demonstrated encouraging antitumor activities. This study aimed to 
      observe the efficacy and safety of apatinib for the treatment of multiple brain 
      micrometastases. CASE SUMMARY: We report two patients with multiple brain 
      micrometastases after failure of second-line treatment. Both patients had 
      extracerebral metastases. When the patients took 250 mg/d apatinib orally, the 
      intracerebral lesions disappeared. The extracerebral lesions were partially 
      alleviated. Both patients had a progression-free survival of more than 12 mo and 
      were still stable. The safety was good. The main adverse events (AEs) were mild 
      hypertension and proteinuria, which could be controlled. CONCLUSION: Apatinib has 
      clear efficacy and good tolerance in patients with multiple brain micrometastases 
      after failure of second-line treatment.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Guo, Jun-Hui
AU  - Guo JH
AD  - Department of Oncology, The Second Affiliated Hospital of Henan University of 
      Chinese Medicine, Henan Province Hospital of TCM, Zhengzhou 450002, Henan 
      Province, China. gjunhui2008@163.com.
FAU - Wang, Yuan-Yuan
AU  - Wang YY
AD  - Department of Oncology, The Second Affiliated Hospital of Henan University of 
      Chinese Medicine, Henan Province Hospital of TCM, Zhengzhou 450002, Henan 
      Province, China.
FAU - Zhang, Jiang-Wei
AU  - Zhang JW
AD  - Department of Oncology, The Second Affiliated Hospital of Henan University of 
      Chinese Medicine, Henan Province Hospital of TCM, Zhengzhou 450002, Henan 
      Province, China.
FAU - Liu, Pei-Min
AU  - Liu PM
AD  - Department of Oncology, The Second Affiliated Hospital of Henan University of 
      Chinese Medicine, Henan Province Hospital of TCM, Zhengzhou 450002, Henan 
      Province, China.
FAU - Hao, Yan-Jun
AU  - Hao YJ
AD  - Department of Oncology, The Second Affiliated Hospital of Henan University of 
      Chinese Medicine, Henan Province Hospital of TCM, Zhengzhou 450002, Henan 
      Province, China.
FAU - Duan, Hai-Rui
AU  - Duan HR
AD  - Department of Oncology, The Second Affiliated Hospital of Henan University of 
      Chinese Medicine, Henan Province Hospital of TCM, Zhengzhou 450002, Henan 
      Province, China.
LA  - eng
PT  - Case Reports
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC7176611
OTO - NOTNLM
OT  - Apatinib
OT  - Brain micrometastases
OT  - Cervical adenocarcinoma
OT  - Esophageal squamous cell carcinoma
OT  - Tyrosine kinase inhibitor
OT  - Vascular endothelial growth factor
COIS- Conflict-of-interest statement: The authors declare no conflicts of interest.
EDAT- 2020/04/28 06:00
MHDA- 2020/04/28 06:01
PMCR- 2020/04/06
CRDT- 2020/04/28 06:00
PHST- 2019/12/17 00:00 [received]
PHST- 2020/03/05 00:00 [revised]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/04/28 06:00 [entrez]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/04/28 06:01 [medline]
PHST- 2020/04/06 00:00 [pmc-release]
AID - 10.12998/wjcc.v8.i7.1326 [doi]
PST - ppublish
SO  - World J Clin Cases. 2020 Apr 6;8(7):1326-1336. doi: 10.12998/wjcc.v8.i7.1326.